Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | GPR3 | P46089 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL1136415 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25301943 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL4367100 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL23430060 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25292878 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25287606 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25285896 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25292546 | 0.92 | GPR3 (0.48) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL20570425 | 0.92 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL25255863 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574135-A | Method for synthesizing 7-oxa-2-azabicyclo [3.3.1] non-3-alkene-1-alcohol by rare earth catalysis | 北京化工大学 | 2026-02-27 | — | — | CN | claimed |
| EP-4685150-A1 | METHOD FOR PRODUCING AMIDE GROUP-CONTAINING COMPOUND USING N-CARBOXYAMINO ACID ANHYDRIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-01-28 | — | — | EP | claimed |
| CN-120058733-A | Organic conjugated small molecule and preparation method thereof | 电子科技大学 | 2025-05-30 | — | — | CN | claimed |
| CN-119930712-A | New synthesis method of 2' -O-alkyl guanosine | 常州合全药业有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-20250084012-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-13 | — | — | US | claimed |
| CN-118576735-B | Application of magnetic resonance contrast agent in targeting adrenal cortex and imaging method | 华中科技大学同济医学院附属协和医院 | 2025-02-14 | — | — | CN | claimed |
| EP-4461715-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUPS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-11-13 | — | — | EP | claimed |
| WO-2024225377-A1 | METHOD FOR PRODUCING AMIDE GROUP-CONTAINING COMPOUND USING N-CARBOXYAMINO ACID ANHYDRIDE | 中外製薬株式会社 | 2024-10-31 | — | — | WO | claimed |
| CN-118697902-A | Application of magnetic resonance gadolinium-based contrast agent in kidney branch vessel development | 华中科技大学同济医学院附属协和医院 | 2024-09-27 | — | — | CN | claimed |
| CN-118638046-A | Method for asymmetric synthesis of pyridine-2-formylnorbornene by rare earth catalysis | 北京化工大学 | 2024-09-13 | — | — | CN | claimed |
| US-8101747-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-01-24 | — | — | US | claimed |
| EP-2241554-B1 | Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts | SERVIER LAB (FR) | 2011-09-07 | — | — | EP | claimed |
| EP-2241553-B1 | Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts | SERVIER LAB (FR) | 2011-07-20 | — | — | EP | claimed |
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-09-30 | — | — | US | claimed |
| US-20100249398-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-09-30 | — | — | US | claimed |
| US-7105686-B2 | Manufacture of tocol, tocol derivatives and tocopherols | DSM IP ASSETS B.V. (NL) | 2006-09-12 | — | — | US | claimed |
| US-20050038269-A1 | Manufacture of tocol, tocol derivatives and tocopherols | DSM IP ASSETS B.V. (NL) | 2005-02-17 | — | — | US | claimed |
| EP-0658552-B1 | Process for the preparation of alpha-tocopherol derivatives | EISAI CO LTD (JP) | 1999-03-31 | — | — | EP | claimed |
| US-5532387-A | CYCLIZATION OF TRIMETHYLHYDROQUINONE AND AN ALKENYL ALCOHOL, REUSABLE CATALYST, IIIB FLUOROSULFONATE, NITRATE, SULFATE, OR FLUOROALKYLSULFONATE | EISAI CO., LTD. (JP) | 1996-07-02 | — | — | US | claimed |
| EP-0658552-A1 | Process for the preparation of alpha-tocopherol derivatives | Eisai Co., Ltd. (JP) | 1995-06-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084012-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUP | TERT, MGMT, MITF | CA1 2060/4885CA2 1471/4885CA7 419/4885 |
| US-20100249398-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | CA1 3006/4885CA2 586/4885CA7 1044/4885 |
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | CA1 3006/4885CA2 586/4885CA7 1044/4885 |
| US-20050038269-A1 | Manufacture of tocol, tocol derivatives and tocopherols | TTPA, OSBPL3, PTGES3 | CA1 2444/4885CA2 2820/4885CA7 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.